LGALS9B (galectin 9B) is a carbohydrate-binding protein with emerging roles in cancer pathogenesis. Primary Function: LGALS9B binds galactosides and regulates protein-protein interactions, functioning as a molecular scaffold that influences cell signaling cascades 1. Mechanism: In gastric cancer, LGALS9B stabilizes the eukaryotic translation elongation factor EEF1D by competing with the E3 ligase HERC5 for binding, preventing EEF1D degradation and subsequently activating the PI3K/AKT signaling pathway 1. Disease Relevance: LGALS9B overexpression promotes gastric cancer cell proliferation, migration, and invasion, while knockdown inhibits these processes both in vitro and in vivo 1. Additionally, LGALS9B methylation status serves as a prognostic biomarker in kidney renal papillary cell carcinoma (KIRP), with specific methylated sites (cg24387542) helping classify patients into risk groups for survival prediction 2. Clinical Significance: LGALS9B is identified as a co-expression partner of PDZ-binding kinase in hepatocellular carcinoma protein interaction networks 3, suggesting involvement in broader cancer-associated signaling networks. These findings position LGALS9B as a potential therapeutic target for managing gastric and renal cancers.